Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
Generation Bio Co. (Nasdaq: GBIO) announced that Phillip Samayoa will present a company overview at the Cell & Gene Meeting on the Mesa, virtually held from Oct. 12-16, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio Co. (Nasdaq: GBIO) announced that Phillip Samayoa will present a company overview at the Cell & Gene Meeting on the Mesa, virtually held from Oct. 12-16, 2020. The presentation will be available for on-demand viewing during the conference. Additionally, CEO Geoff McDonough, M.D., will participate in a panel discussion on gene delivery, accessible from Oct. 13. Generation Bio focuses on innovative, non-viral gene therapy for durable treatments of rare and prevalent diseases using proprietary technologies aimed at scalable and effective gene delivery.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +7.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Phillip Samayoa, vice president of strategy and portfolio development, will present a company overview at the annual Cell & Gene Meeting on the Mesa. The presentation will be available for registered participants to view on demand throughout the conference, to be held virtually Oct. 12-16, at meetingonthemesa.com.
Geoff McDonough, M.D., Generation Bio’s president and chief executive officer, will participate in a panel on the future of gene delivery. That discussion will be available to view on demand on the conference website starting Oct. 13.
About Generation Bio
Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.
For more information, please visit generationbio.com.
Contact:
Investors
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
910-777-3049
Media
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.